Full-Time

Director HCP Inflammation Marketing

Posted on 10/2/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$185.8k - $242.6k/yr

Princeton, NJ, USA

Hybrid

Hybrid role; minimum 2 days/week in Princeton Home Office.

Category
Growth & Marketing (3)
, ,
Requirements
  • Bachelor’s degree required
  • MBA preferred
  • Minimum 6 years HCP pharmaceutical marketing in inflammatory disease (Dermatology or Allergy) in both traditional and digital marketing in the complex biologics space
  • Recent launch experience
  • Successful experience within a highly collaborative alliance environment
  • Outstanding leadership, project management and presentation skills
  • Experience in dermatology and/or allergy preferred
  • Sales, Sales management, managed care or market research experience a plus
  • Proficient in MS Office Suite
Responsibilities
  • Leads the collaborative planning, alignment, approval and execution of HCP marketing strategies and tactics designed to drive US performance.
  • Works to create the US commercial plan for the pipeline of inflammation products with cross-functional and alliance partners.
  • Effective execution of a full complement of strategically driven HCP programs through positive, productive and collaborative relationships with alliance partners and external agency partners.
  • Drives alignment with strategic objectives and brand communications across the organization (Sales, Training, Marketing, business Insights & Analytics, Market Access, Patient Services, Legal, Medical, Supply, Public Affairs, etc.).
  • Ensures key promotional programs are managed effectively achieving KPIs on time and on budget.
  • Facilitates a smooth running and compliant PRC process in concert with the PRC team and partner agencies.
  • Liaises with Sales Management and contributes significantly to selling strategy development, training and targeting
  • Utilizes Field Advisory Teams to collect input on tactics, performance, opportunities and challenges, as well as test materials
  • Ensures smooth and effective execution of POA and rollout of training and promotional initiatives
  • Partners with business analytics team on market research projects to gain actionable insights and measure performance
Desired Qualifications
  • Education: MBA preferred
  • Experience in oncology/hematology or related fields is not listed as Desirable here, so skip
  • Physical Demands etc. not desired
  • Hybrid position requiring a minimum of 2 days/week in the Princeton Home Office is a Working Condition, not Desirable

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE